Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Nature Communications|October 31, 2020
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancerKyung-Min Lee, Angel L Guerrero-Zotano, Alberto Servetto, et al.
Cancer Cell|June 25, 2021
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivityAriella B Hanker, Benjamin P Brown, Jens Meiler, et al.
Cancer Discovery|March 10, 2017
An Acquired <i>HER2</i><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast CancerAriella B Hanker, Monica Red Brewer, Jonathan H Sheehan, et al.
Biorxiv : the Preprint Server for Biology|October 2, 2023
Mapping Cellular Interactions from Spatially Resolved Transcriptomics DataJames Zhu, Yunguan Wang, Woo Yong Chang, et al.
Nature Methods|September 3, 2024
Mapping cellular interactions from spatially resolved transcriptomics dataJames Zhu, Yunguan Wang, Woo Yong Chang, et al.
Nature Cancer|May 29, 2023
Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastasesPravat Kumar Parida, Mauricio Marquez-Palencia, Suvranil Ghosh, et al.
Cancer Cell|January 25, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant CancersDhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Cell Metabolism|January 5, 2022
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitnessPravat Kumar Parida, Mauricio Marquez-Palencia, Vidhya Nair, et al.
Cancer Research|January 8, 2024
AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast CancerMauricio Marquez-Palencia, Luis Reza Herrera, Pravat Kumar Parida, et al.
Research Square|July 28, 2023
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancerChang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, et al.
Pageof 4